Grace Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $32.47M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2027 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | – | $-0.91 | – |
| Q4 FY2026 Ended Mar 31, 2026 | Jun 18, 2026 | Before market open | – | – | – |
| Q3 FY2026 Ended Dec 31, 2025 | Feb 12, 2026 | Before market open | – | $-0.14 | – |
| Q2 FY2026 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | – | $-0.06 | – |
| Q1 FY2026 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | – | – | – |
| Q4 FY2025 Ended Mar 31, 2025 | Jun 23, 2025 | Before market open | – | – | – |
| Q3 FY2025 Ended Dec 31, 2024 | Feb 13, 2025 | Before market open | – | $-0.36 | – |
| Q2 FY2025 Ended Sep 30, 2024 | Nov 13, 2024 | Before market open | – | $-0.30 | – |
| Q1 FY2025 Ended Jun 30, 2024 | Aug 9, 2024 | Before market open | – | $-0.24 | – |
| Q4 FY2024 Ended Mar 31, 2024 | Jun 21, 2024 | Before market open | – | – | – |
| Q3 FY2024 Ended Dec 31, 2023 | Feb 12, 2024 | Before market open | – | $-0.21 | – |
Press releases
Announcements Grace Therapeutics filed with the SEC
Grace Therapeutics Announces First Quarter 2027 Financial Results,
Results of operations · EX-99.1 to Form 8-K
Grace Therapeutics Announces $10 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Grace Therapeutics Announces Receipt of Type A Meeting Minutes
Other events · EX-99.1 to Form 8-K
Corporate Presentation Late Summer 2026
Other events · EX-99.2 to Form 8-K
Summary 2 Forward Looking Statements Statements in this presentation that are
Other events · EX-99.1 to Form 8-K
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results,
Results of operations · EX-99.1 to Form 8-K
Summary 2 Forward Looking Statements Statements in this presentation that are
Other events · EX-99.1 to Form 8-K
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
Other events · EX-99.1 to Form 8-K
Grace Therapeutics Announces Third Quarter 2026 Financial Results,
Results of operations · EX-99.1 to Form 8-K
Grace Therapeutics Announces Second Quarter 2026 Financial Results,
Results of operations · Other events · EX-99.1 to Form 8-K
Summary 2 Forward Looking Statements Statements in this presentation that are
Results of operations · Other events · EX-99.2 to Form 8-K
Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New
Other events · EX-99.1 to Form 8-K
Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104
Other events · EX-99.1 to Form 8-K
Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104
Other events · EX-99.1 to Form 8-K
Grace Therapeutics Announces First Quarter 2026 Financial Results,
Results of operations · EX-99.1 to Form 8-K
Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104
Other events · EX-99.1 to Form 8-K
Grace Therapeutics Announces 2025 Fiscal Year-End Results,
Results of operations · EX-99.1 to Form 8-K
Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104
Other events · EX-99.1 to Form 8-K
Summary 2 Forward Looking Statements Statements in this presentation that are
Other events · EX-99.1 to Form 8-K
Grace Therapeutics Announces Third Fiscal Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Summary 2 Forward Looking Statements Statements in this presentation that are
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Grace Therapeutics Announces Private Placement Financing of up to $30 Million
Material agreement · Unregistered share sale · Other events · EX-99.3 to Form 8-K
Grace Therapeutics Announces Second Fiscal Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Acasti Announces Corporate Name Change
Other events · EX-99.1 to Form 8-K
Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
Other events · EX-99.1 to Form 8-K
Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial
Other events · EX-99.1 to Form 8-K
Acasti Announces Year-End 2024 Financial Results, Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Company Overview NASDAQ: ACST April 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial
Material agreement · Other events · EX-99.1 to Form 8-K
Acasti Announces $7.5 Million Private Placement Equity Financing
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Acasti Announces First Quarter 2024 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Acasti Pharma Announces 1-for-6 Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Acasti Pharma Reports Fiscal Year 2023 Operational Results
Results of operations · EX-99.1 to Form 8-K
Acasti Announces Appointment of Prashant Kohli as CEO
Executive or director change · Regulation FD disclosure · Other events · EX-99 to Form 8-K
Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND
Executive or director change · Regulation FD disclosure · Other events · EX-99#2 to Form 8-K